Facebook Linkedin Twitter
Inside Precision Medicine Lorlatinib Found Effective against ALK-Driven High-Risk Neuroblastoma

Phase III clinical trials (Clinical trial)

Real fluorescence microscopic view of human neuroblastoma cells
News & Features

Lorlatinib Found Effective against ALK-Driven High-Risk Neuroblastoma

0
Human heart showing surrounding veins and arteries to represent cardiovascular disease such as heart failure.
News & Features

Cell Therapy for Heart Failure Shows Benefit at Phase III

0
Luminous double helix strands of abstract DNA, 3D render.
News & Features

C4XD Launches Precision Medicine Platform

0
Cancer associated fibroblasts layer on tumor microenvironment
News & Features

First Reversible BTK Inhibitor, Jaypirca, Approved for Mantle Cell Lymphoma

0
Human bone marrow under the microscope to illustrate myelofibrosis blood cancer, the diagnosis of which could be aided by new AI tools
News & Features

Momelotinib Performs Well at Phase III in Rare Bone Marrow Cancer Patients

0
Alzheimer: Phosphorylation of Tau proteins leads to disintegration of microtubuli in a neuron axon
News & Features

Tau PET Diagnostic Imaging Agent Enters Phase III Clinical Study

0
Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy
News & Features

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

0
Rainbow DNA
News & Features

Amgen Acquires Rare Disease Company Horizon Tx for Almost $28 Billion

0
IBD, Crohn's disease, ulcerative colitis
News & Features

Prometheus’ $500M Public Offering to Fund Phase III UC, Crohn’s Studies

0
NK Cell (Natural Killer Cell) Attacking a Cancer Cell
News & Features

Keytruda Shines in Phase III Gastric Cancer Trial

0
1...345Page 4 of 5

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine